Blood tests reveal how AML drug works in real patients

NCT ID NCT07243483

Recruiting now Knowledge-focused Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 22 times

Summary

This study looks at how the drug venetoclax behaves in the bodies of people with acute myeloid leukemia (AML). Researchers will take extra blood samples to measure drug levels and see how they relate to treatment response. About 100 adults starting venetoclax plus azacitidine will join. The study does not change their regular care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU de Grenoble
RECRUITING

Grenoble, 38000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
CHU de Saint-Étienne
RECRUITING

Saint-Etienne, 42100, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Centre Hospitalier Pierre Oudot
RECRUITING

Bourgoin, France, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Centre Leon Berard
RECRUITING

Lyon, 69008, France

Contact Email: •••••@•••••
Hôpitaux Nord-Ouest - Villefranche-sur-Saône
RECRUITING

Villefranche-sur-Saône, 69400, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA